

Jiri Pavlu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/105128/publications.pdf>

Version: 2024-02-01

56
papers

706
citations

759233

12
h-index

580821

25
g-index

56
all docs

56
docs citations

56
times ranked

1184
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy. <i>British Journal of Haematology</i> , 2022, 196, 368-373.	2.5	2
2	Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 399-406.	2.4	9
3	Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 562-571.	2.4	16
4	Disease Prevention Not Decolonization: A Model for Fecal Microbiota Transplantation in Patients Colonized With Multidrug-resistant Organisms. <i>Clinical Infectious Diseases</i> , 2021, 72, 1444-1447.	5.8	40
5	Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 171.e1-171.e8.	1.2	9
6	Augmented Reduced-Intensity Regimen Does Not Improve Postallogeic Transplant Outcomes in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 768-778.	1.6	95
7	High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2690-2696.	2.4	6
8	Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 684659.	3.9	14
9	How I Use Measurable Residual Disease in the Clinical Management of Adult Acute Lymphoblastic Leukemia. <i>Clinical Hematology International</i> , 2021, 3, 130.	1.7	6
10	Complete remission with incomplete count recovery (CRI) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality. <i>Leukemia</i> , 2020, 34, 667-670.	7.2	10
11	The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants. <i>Nature Communications</i> , 2020, 11, 1044.	12.8	81
12	Reducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan Protocol Harmonization Initiative. <i>Bone Marrow Transplantation</i> , 2020, 55, 1840-1843.	2.4	3
13	Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 2766-2775.	7.2	30
14	Reduced Intensity Vs. Non-Myeloablative Conditioning Regimens for Haploidentical Transplantation in Complete Remission Acute Myeloid Leukemia: A Study from the ALWP of the EBMT. <i>Blood</i> , 2020, 136, 9-9.	1.4	0
15	Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. <i>Journal of Hematology and Oncology</i> , 2019, 12, 108.	17.0	51
16	Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study. <i>Advances in Therapy</i> , 2019, 36, 870-879.	2.9	4
17	Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies. <i>Clinical Nutrition</i> , 2019, 38, 738-744.	5.0	37
18	The Sequential Flamsa-Bu Conditioning Regimen Does Not Improve Outcome in Patients Allografted for High Risk Acute Myeloid and Myelodysplasia Irrespective of Pre-Transplant MRD Status: Results of the UK NCRI Figaro Trial. <i>Blood</i> , 2019, 134, 2031-2031.	1.4	4

#	ARTICLE	IF	CITATIONS
19	Bone Marrow Versus Mobilized Peripheral Blood Stem Cells for Non T Depleted Haploidentical Transplantations with Post Transplantation Cyclophosphamide in Acute Lymphoblastic Leukemia: On Behalf of the ALWP of the EBMT. <i>Blood</i> , 2019, 134, 589-589.	1.4	0
20	C-reactive protein prior to myeloablative allogeneic haematopoietic cell transplantation identifies patients at risk of early and long term mortality. <i>British Journal of Haematology</i> , 2018, 180, 889-892.	2.5	6
21	34-Year Single Center Observational Review of Ex-Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplants for Chronic Myeloid Leukemia. <i>Blood</i> , 2018, 132, 5746-5746.	1.4	0
22	Incidence and Risk Factors for Second Malignancies after Transplant in Long Term Survivors of Allogeneic Haematopoietic Stem Cell Transplant: A Single Centre Experience. <i>Blood</i> , 2018, 132, 3417-3417.	1.4	0
23	BK-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation. <i>European Journal of Haematology</i> , 2017, 98, 632-634.	2.2	36
24	Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT. <i>Cancer</i> , 2017, 123, 1965-1970.	4.1	31
25	Impact of Nutrition on Non-Relapse Mortality and Acute Graft Versus Host Disease during Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Blood</i> , 2016, 128, 2226-2226.	1.4	1
26	Clinical Efficacy of BK Virus Specific T-Cells in Treatment of Severe Refractory Hemorrhagic Cystitis after HLA Haploidentical Transplantation. <i>Blood</i> , 2016, 128, 5726-5726.	1.4	3
27	Microbial Contamination of Haematopoietic Stem Cell Products: A Single Centre Experience. <i>Blood</i> , 2016, 128, 5741-5741.	1.4	2
28	Preconditioning Neutropenia Is a Key Prognostic Factor in Allogeneic Hematopoietic Cell Transplantation for High Risk Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 3411-3411.	1.4	0
29	Allogeneic Hematopoietic Stem Cell Transplantation for Primary Refractory Acute Lymphoblastic Leukemia - a Report from the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2016, 128, 4668-4668.	1.4	0
30	The cytological features of <i>NPM1</i> -mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2015, 90, 560-560.	4.1	6
31	Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 43-51.	2.3	8
32	Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing. <i>Blood</i> , 2013, 122, 740-740.	1.4	0
33	Stem cell transplantation: its importance today. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 277-280.	0.5	0
34	Third Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma. <i>Blood</i> , 2012, 120, 4548-4548.	1.4	0
35	Tandem Autologous Stem Cell Transplantation in Chemorefractory Multiple Myeloma. <i>Blood</i> , 2012, 120, 4554-4554.	1.4	0
36	Three decades of transplantation for chronic myeloid leukemia: what have we learned?. <i>Blood</i> , 2011, 117, 755-763.	1.4	103

#	ARTICLE	IF	CITATIONS
37	LACEâ€conditioned autologous stem cell transplantation for relapsed or refractory diffuse large Bâ€cell lymphoma: treatment outcome and risk factor analysis from a single centre. Hematological Oncology, 2011, 29, 75-80.	1.7	9
38	Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib. Blood, 2011, 118, 1680-1680.	1.4	3
39	Cryopreserved Allogeneic Peripheral Blood Stem Cells Result in Outcome Equivalent to Those of Fresh Infusions Enabling Rational Scheduling of Donations,. Blood, 2011, 118, 4052-4052.	1.4	0
40	Elevated Preconditioning Serum Levels of C-Reactive Protein Are Associated with Increased Nonrelapse Mortality and Inferior Survival After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2011, 118, 1945-1945.	1.4	0
41	Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood, 2010, 115, 4018-4020.	1.4	56
42	High Frequency and Cell Dose of Invariant NKT Cells In the Graft Are Associated with Lack of Clinically Significant Acute Gvhd In T Cell-Replete Sibling Allografts. Blood, 2010, 116, 2539-2539.	1.4	1
43	2009 Pandemic Influenza A H1N1 Vaccination In the Patients with Hematologic Malignancies: Requirement for Repeated Dosing to Optimize Seroprotection. Blood, 2010, 116, 677-677.	1.4	0
44	Response to Tyrosine Kinase Inhibitor Therapy In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Phase Chronic Myeloid Leukemia. Blood, 2010, 116, 3515-3515.	1.4	0
45	Hematopoietic Chimerism LEVELS ARE RELATED to RELAPSE and GRAFT VERSUS Host DISEASE IN REDUCED INTENSITY Allogeneic STEM CELL Transplantation. Blood, 2010, 116, 4702-4702.	1.4	0
46	Preconditioning Level of C-Reactive Protein and Disease Stage Are Key Prognostic Factors In Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2010, 116, 3488-3488.	1.4	0
47	Second Autologous Stem Cell Transplantation Is Effective Salvage Therapy for Relapsed Multiple Myeloma.. Blood, 2009, 114, 1229-1229.	1.4	2
48	Ethnic Disparity in Access to Stem Cell Transplantation for Multiple Myeloma.. Blood, 2009, 114, 1781-1781.	1.4	0
49	The Combination of Cyclophosphamide and Thalidomide During Induction Therapy for Multiple Myeloma Results in a High Rate of Stem Cell Mobilization Failure.. Blood, 2009, 114, 2147-2147.	1.4	0
50	Optimizing Patient Selection for Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia.. Blood, 2009, 114, 3392-3392.	1.4	4
51	Prediction of Cytogenetic Response to Second Generation TKI Therapy in CML Chronic Phase Patients Who Have Failed Imatinib Therapy and Early Identification of Factors That Influence Survival. Blood, 2008, 112, 332-332.	1.4	7
52	Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era.. Blood, 2008, 112, 970-970.	1.4	0
53	Incorporating Marrow Plasma Cell Infiltration at Diagnosis and Cytogenetic Features into Prognostic Scoring at Point of Autologous Stem Cell Transplantation for Multiple Myeloma. Blood, 2008, 112, 3319-3319.	1.4	0
54	Pneumococcal septicaemia. Lancet Infectious Diseases, The, 2007, 7, 234.	9.1	0

#	ARTICLE	IF	CITATIONS
55	Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission. British Journal of Haematology, 2007, 137, 423-428.	2.5	10
56	GM1-gangliosidosis type I. British Journal of Haematology, 2006, 135, 422-422.	2.5	1